PT 141
Product information
$0
Description
PT-141 was approved by the FDA in June 2019 for the treatment of acquired, generalized HSDD in premenopausal women. It activates melanocortin receptors.
PT-141 is used for the treatment of erectile dysfunction in men and for the treatment of hypoactive sexual desire disorder in women, regulating sexual desire and sexual response, and helping premenopausal women with low sexual desire disorders maintain normal sexual desire.
